Late-onset distant metastases confer poor prognosis in patients with well-differentiated thyroid cancer

被引:8
作者
Jung, Chan Kwon [1 ,2 ]
Lee, Sohee [3 ]
Bae, Ja Seong [3 ]
Lim, Dong-Jun [4 ]
机构
[1] Catholic Univ Korea, Coll Med, Dept Hosp Pathol, Seoul, South Korea
[2] Catholic Univ Korea, Coll Med, Canc Res Inst, Seoul, South Korea
[3] Catholic Univ Korea, Coll Med, Dept Surg, Seoul, South Korea
[4] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Thyroid cancer; papillary carcinoma; follicular carcinoma; distant metastasis; synchronous; metachronous; prognosis; TERT PROMOTER MUTATIONS; THYROGLOBULIN DOUBLING-TIME; CLINICAL MANAGEMENT; CARCINOMA; ASSOCIATION; PAPILLARY; IMPACT; GUIDELINES; OUTCOMES;
D O I
10.21037/gs-20-416
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Distant metastases from well-differentiated thyroid carcinoma (WDTC) occasionally occur over a wide range of time intervals after primary thyroid surgery. The prognostic impact of the timing of distant metastasis onset remains unclear. Methods: We retrospectively reviewed the clinicopathologic features and clinical outcomes of 57 patients with WDTC and distant metastases, and evaluated the mutational profiles of BRAF, RAS, and TERT promoter genes. All patients underwent thyroidectomy and radioactive iodine (RAI) ablation using the same treatment protocol. Synchronous distant metastases were defined as those detected within 12 months of the primary WDTC diagnosis. Metachronous metastases were considered early- and late-onset diseases if detected 1-5 and ?5 years after the primary diagnosis, respectively. Results: In all patients, the 5- and 10-year cancer-specific survival (CSS) rates after the diagnosis of distant metastasis were 86% and 57%, respectively. Late-onset (>= 5 years) metachronous distant metastasis was associated with age of >= 55 years (P=0.043) and patients refractory to RAI therapy (P=0.026). TERT promoter mutations were associated with RAI refractivity (P=0.026). BRAF V600E and RAS mutations had no prognostic significance. Bone metastasis (P=0.002) and the onset time of distant metastasis (P=0.004) were associated with poor CSS. There was no significant difference in CSS between patients with synchronous distant metastases and those with early-onset (1-5 years) metachronous distant metastases. In the multivariate analysis, bone metastasis [hazard ratio (HR) =10.24; 95% confidence interval (CI): 1.25-83.74; P=0.030] and late-onset (>= 5 years) metachronous distant metastasis (HR =5.20; 95% CI: 1.01-26.63; P=0.048) were independent predictors for worse CSS. Conclusions: The prognosis of patients with WDTC was poorer for late metachronously detected metastases than for synchronous or early metachronous metastases. Patients with distant metastasis occurring 5 years later after primary thyroid diagnosis should, therefore, be more carefully treated.
引用
收藏
页码:1857 / 1866
页数:10
相关论文
共 39 条
[31]  
Schlumberger Martin, 2015, F1000Prime Rep, V7, P22, DOI 10.12703/P7-22
[32]   A Multi-institutional Study of Prevalence and Clinicopathologic Features of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP) in Korea [J].
Seo, Ja Yeong ;
Park, Ji Hyun ;
Pyo, Ju Yeon ;
Cha, Yoon Jin ;
Jung, Chan Kwon ;
Song, Dong Eun ;
Kwak, Jeong Ja ;
Park, So Yeon ;
Na, Hee Young ;
Kim, Jang-Hee ;
Seok, Jae Yeon ;
Kim, Hee Sung ;
Hong, Soon Won .
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2019, 53 (06) :378-385
[33]   Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma [J].
Shoup, M ;
Stojadinovic, A ;
Nissan, A ;
Ghossein, RA ;
Freedman, S ;
Brennan, MF ;
Shah, JP ;
Shaha, AR .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2003, 197 (02) :191-197
[34]   Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer [J].
Sohn, Seo Young ;
Park, Woong Yang ;
Shin, Hyun Tae ;
Bae, Joon Seol ;
Ki, Chang Seok ;
Oh, Young Lyun ;
Kim, Sun Wook ;
Chung, Jae Hoon .
THYROID, 2016, 26 (05) :672-682
[35]   Thyroglobulin antibody (TgAb) methods - Strengths, pitfalls and clinical utility for monitoring TgAb-positive.patients with differentiated thyroid cancer [J].
Spencer, Carole ;
Fatemi, Shireen .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 27 (05) :701-712
[36]   Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas [J].
Wassermann, Johanna ;
Bernier, Marie-Odile ;
Spano, Jean-Philippe ;
Lepoutre-Lussey, Charlotte ;
Buffet, Camille ;
Simon, Jean-Marc ;
Menegaux, Fabrice ;
Tissier, Frederique ;
Leban, Monique ;
Leenhardt, Laurence .
ONCOLOGIST, 2016, 21 (01) :50-58
[37]   Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma [J].
Xu, Bin ;
Ghossein, Ronald .
ENDOCRINE PATHOLOGY, 2016, 27 (03) :205-212
[38]   Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis [J].
Yang, Jing ;
Gong, Yanping ;
Yan, Shuping ;
Chen, Hui ;
Qin, Siqin ;
Gong, Rixiang .
ENDOCRINE, 2020, 67 (01) :44-57
[39]   The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence [J].
Yin, Ngwe ;
Sherman, Steven, I ;
Pak, Youngju ;
Litofsky, Danielle R. ;
Gianoukakis, Andrew G. .
THYROID, 2020, 30 (10) :1490-1495